ABSTRACT
David Resnik accurately describes the problem faced by developing countries in securing affordable drugs aimed at their particular disease burden. 1 I am, however, skeptical of the solution he describes, which appeals to the respective ‘social responsibilities’ of global pharmaceutical companies and developing countries. I am not persuaded we can derive his claims about such responsibilities in the way he does or that appealing to them solves the problems of commitment and enforcement that must be addressed in any realistic solution. I offer some reasons for that skepticism, realizing full well that my brief remarks cannot do justice to his view.
